S&P 500 7718.60 -0.38%
NASDAQ 26506.99 -0.29%
TASI 11024.73 -0.40%
Oil (WTI) 91.48 +0.00%
Oil (Brent) 96.28 +0.00%
VIX 15.30 +5.30%
Gold 4476.60 +0.00%
USD/SAR 3.76 +0.02%

Merck & Co., Inc.

MRK · Healthcare · · USD
150.33 USD
0.00 (-1.32%)
● Updated 2026-09-07 19:34 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score STRONG BUY Mid-term (Position)

81
/ 100
Technical 75
Trend & RS 98
Momentum 91
Fundamental 78
Macro 64
Liquidity 48
ComponentScoreWeight
Technical 75.0 20%
Trend & RS 97.6 30%
Momentum 91.0 15%
Fundamental 77.8 10%
Macro 64.4 20%
Liquidity 48.1 5%

Trade Setup

Entry 150.33
Stop Loss 142.39 (5.3%)
Target 1 (1:1) 158.27 (+5.3%)
Target 2 (2:1) 166.21 (+10.6%)
ATR(14) 3.97 (2.6%)
Risk per Share 7.94
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 22.5 -1.10
Momentum 91.0 +1.64
Quality 29.0 -0.84
Composite 47.5

Quality Scores

Piotroski F-Score 5 /9 — Average
✓ ✓ ✗ ✗ ✗ ✗ ✓ ✓ ✓
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score 6.09 — Safe Zone
Distress <1.81Grey 1.81–2.99>2.99 Safe

Valuation vs Peers Overvalued

MetricStockSectorvs Peers
P/E Ratio 120.3 22.0 +447% above
P/B Ratio 8.8 4.0 Above
Dividend Yield 2.2% 1.5% Above avg

Comparing against Healthcare median multiples.

Trading at a premium to sector peers — verify growth justifies premium.

Intrinsic Value (DCF) Significantly Overvalued

Intrinsic Value
17.63
vs
Market Price
150.33
Upside
-88.3%
Margin of Safety -752.6%
Stage 1 PV (5yr FCF)11,073,232,169
Terminal Value PV32,425,819,668
Total Enterprise Value43,499,051,837

Assumptions

Base FCF2,467,171,638
Growth Rate (5yr)5.1%
Terminal Growth2.5%
Discount Rate (WACC)9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.5%
Recommended Size
52.06%
Full Kelly
26.03%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 81/100. Estimated win rate 64%, avg win 9.9%, avg loss 3.4%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary STRONG BUY

3
Bullish Signals
1
Bearish Signals
62.3
RSI(14)
5.4978
MACD

Relative Strength (RS) IMPROVING

93
/ 99
RS Rating
✓ O'Neil PASS (≥80)
RS vs SPY ↑ RISING (+20.7% vs SPY 3M)
RS vs Sector OUTPERFORMING (Healthcare)
RS New High No (8d since high)
Sector Outperformance +17.6% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
IMPROVING: Gaining momentum — the stock is starting to outperform the market. Watch for RS new high confirmation.

Technical Indicators

IndicatorValueSignal
Rsi 62.3 NEUTRAL
Macd 5.4978 BEARISH
Ma Cross 134.59 / 117.44 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.4x LOW

Key Levels

LevelPrice
52-Week High156.92
Bollinger Upper162.51
SMA(200)117.44
SMA(50)134.59
SMA(20)145.03
Current Price150.33
Bollinger Lower127.55
52-Week Low77.58
ATR(14)3.97

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

DISTRIBUTION A Confidence
50%
Buying Climax
Acc: 0.0  |  Dist: 2.0  |  Markup: 2.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-08-31 Normal 1.02x Normal bar — no special VSA pattern
2026-09-01 Normal 0.91x Normal bar — no special VSA pattern
2026-09-02 Normal 0.83x Normal bar — no special VSA pattern
2026-09-03 Normal 0.6x Normal bar — no special VSA pattern
2026-09-04 No Demand 0.4x Low volume, narrow spread, weak close — no buying interest

Ichimoku Cloud BULLISH

LineValueStatus
Tenkan-sen (9) 151.33 Above Kijun
Kijun-sen (26) 141.57 Base line
Senkou A 146.45 Leading span A
Senkou B 138.22 Leading span B
Cloud 138.22 – 146.45 Bullish (Green)
Price vs Cloud 150.33 Above Cloud
Chikou Span 130.20 Bullish
Alignment Score 4/4 BULLISH

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH FADING
BB: 127.55 – 162.51  |  KC: 138.48 – 151.58

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Hidden Bullish RSI 5

Anchored VWAP

VWAP: 110.74 Anchor: 2025-09-25 (52w Low) ABOVE AVWAP +35.8%

Heikin-Ashi Trend

WEAKLY BEARISH Full data via /api/advanced/MRK

Valuation

MetricValue
Market Cap370.89B
P/E (TTM)120.26
Forward P/EN/A
P/B8.85
EPS1.25

Financial Health

MetricValue
Revenue Growth5.1%
Profit Margin4.8%
ROE7.0%
Debt/Equity128.41
Current Ratio1.32
Dividend Yield2.2%
Payout RatioN/A
Beta0.23

Trading Data

150.33
Open
150.33
Day High
150.33
Day Low
4.30M
Volume (0.4x avg)

Recent News (8)

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
MarketBeat · 2026-09-06
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zacks · 2026-09-04
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Barrons.com · 2026-09-04
Revolution Medicines Got Its Breakthrough—What Moves It Next?
MarketBeat · 2026-09-04
Could Merck (MRK) Change Cholesterol Treatment With The First Oral PCSK9 Pill?
Simply Wall St. · 2026-09-04
Was JNJ Stock Rally Actually Its Own?
Trefis · 2026-09-04
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Zacks · 2026-09-04
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
Insider Monkey · 2026-09-04

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —